达格列净治疗糖尿病伴微量白蛋白尿的效果观察  

Effect Observation of Dapagliflozin in Treatment of Diabetes Mellitus with Microalbuminuria

作　　者：杨鸿雁 Yang Hongyan(Department of General Practice,Beitaipingzhuang Community Health Service Center in Haidian District,Beijing 100082,China)

机构地区：[1]北京市海淀区北太平庄社区卫生服务中心全科,北京100082

出　　处：《中国社区医师》2024年第2期49-51,共3页Chinese Community Doctors

摘　　要：目的:分析达格列净治疗糖尿病伴微量白蛋白尿的效果。方法:选取2021年1—12月北京市海淀区北太平庄社区卫生服务中心收治的糖尿病伴微量白蛋白尿患者60例作为研究对象,随机分为两组,各30例。对照组在常规治疗基础上加用磷酸西格列汀,试验组在常规治疗基础上加用达格列净治疗。比较两组血糖水平、肾小球滤过率(e GFR)和尿白蛋白与肌酐比值(UACR)、血压水平、体质量指数(BMI)、不良反应发生情况。结果:治疗前后,两组空腹血糖(FBG)、餐后2 h血糖(2 h PBG)、糖化血红蛋白(Hb A_(1c))水平比较,差异无统计学意义(P>0.05);治疗后,两组FBG、2 h PBG、Hb A_(1c)水平低于治疗前,差异有统计学意义(P<0.05)。治疗前后,两组e GFR水平比较,差异无统计学意义(P>0.05)。治疗前,两组UACR水平比较,差异无统计学意义(P>0.05);治疗后,试验组UACR水平低于治疗前及同期对照组,差异有统计学意义(P<0.05)。治疗前后,两组舒张压、BMI比较,差异无统计学意义(P>0.05)。治疗前,两组收缩压(SBP)水平比较,差异无统计学意义(P>0.05);治疗后,试验组SBP水平低于治疗前与同期对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:达格列净治疗糖尿病伴微量白蛋白尿的效果显著,可降低患者血糖、尿白蛋白、SBP水平,且安全性较高。Objective:To analyze the effect of dapagliflozin in the treatment of diabetes mellitus with microalbuminuria.Methods:A total of 60 patients with diabetes mellitus and microalbuminuria who were managed at the Beitaipingzhuang Community Health Service Center in Haidian District of Beijing from January 2021 to December 2021 were selected as the study subjects.They were randomly divided into two groups,with 30 cases in each group.The control group was treated with sitagliptin phosphate on the basis of conventional treatment,and the experimental group was treated with dapagliflozin on the basis of conventional treatment.The blood glucose levels,estimated glomerular filtration rate (e GFR),urinary albumin to creatinine ratio (UACR),blood pressure levels,body mass index (BMI),and occurrence of adverse reactions were compared between two groups.Results:Before and after treatment,there was no significant difference in the levels of fasting blood glucose (FBG),2 h postprandial blood glucose (2 h PBG)and glycosylated hemoglobin (Hb A_(1c)) between the two groups (P>0.05);After treatment,the levels of FBG,2 h PBG and Hb A_(1c)in the two groups were lower than those before treatment,and the difference was statistically significant (P<0.05).Before and after treatment,there was no significant difference in e GFR levels between the two groups (P>0.05).Before treatment,there was no significant difference in UACR level between the two groups (P>0.05);After treatment,the UACR level in the experimental group was lower than that before treatment and that in the control group,and the difference was statistically significant (P<0.05).Before and after treatment,there was no significant difference in diastolic blood pressure and BMI between the two groups (P>0.05).Before treatment,there was no significant difference in systolic blood pressure (SBP) level between the two groups (P>0.05);After treatment,the SBP level in the experimental group was lower than that before treatment and that in the control group,and the difference was statisti

关 键 词：达格列净 糖尿病 微量白蛋白尿 

分 类 号：R587.1[医药卫生—内分泌]